Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
Posters to feature ex vivo and in-human data supporting Kaleido’s Microbiome Metabolic Therapy programs for the treatment of hyperammonemia LEXINGTON, Mass., March 27, 2019 (GLOBE NEWSWIRE) --...
-
Studies are evaluating novel Microbiome Metabolic Therapies, KB195 and KB174, in target patient populations; data expected in Q4 2019 Third non-IND clinical study in healthy subjects also underway to...
-
LEXINGTON, Mass., March 08, 2019 (GLOBE NEWSWIRE) -- Kaleido Biosciences, (Nasdaq: KLDO), a clinical-stage healthcare company with a differentiated, chemistry-driven approach to leveraging the...
-
LEXINGTON, Mass., March 04, 2019 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a differentiated, chemistry-driven approach to leveraging the...
-
LEXINGTON, Mass., Feb. 27, 2019 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a differentiated, chemistry-driven approach to leveraging the...